The role of early dialysis in the evolution of patients with COVID19

Not Applicable

Recruiting

• Conditions: Coronavirus infection, unspecified; Acute renal failure; B34.2

• Registration Number: RBR-3rdhgm
• Lead Sponsor: Departamento de Clínica Médica da Faculdade de Medicina de Botucatu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-14
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

patients over 18 years old; COVID-19 positive by the RT-PCR technique or rapid test; in mechanical ventilation; diagnosis of AKI; hydric balance positive higher then 3% of body weight; hospitalized in the ICU;vusing norepinephrine at a dose of 0.1 to 1 µg / kg / min.

Exclusion Criteria

Pregnant patients; patients who were on other types of dialysis support, other than HDP or HDC, that with an emergency indication for RAS; diagnosed with stage 5 chronic kidney disease or need for chronic renal replacement therapy (dialysis or transplantation) will be excluded.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Control groups and intervention groups will be compared in relation to the prognosis (time of mechanical ventilation, ICU admission and mortality in 60 days between groups). Variables with normal distribution will be described as mean ± standard deviation and variables with non-normal distribution as median and interquartile range. Comparisons of continuous variables between the two groups will be performed using Student's t test for data with normal distribution and Mann-Whitney test for non-normal data. For the comparative analysis of categorical variables, the Chi-Square tests will be used. For comparisons of variables between groups by sessions, the mixed model of analysis of repeated measures over time with adjustment for Tukey will be used. Univariate and multivariate linear regression will be used for association with mechanical ventilation time and 60-day survival.<br>In all tests performed, the significance level of 5% will be considered.

Secondary Outcome Measures

Name	Time	Method
Dialysis dose received, by calculating kt / V based on the urea kinetics model;metabolic control and volume <br>;removal of cytokines, assessed by quantifying cytokines in blood sample and dialysis effluent at the beginning and end of therapy;dialysis complications